154 related articles for article (PubMed ID: 10654915)
1. Soluble Fas in serum from patients with renal cell carcinoma.
Nonomura N; Nishimura K; Ono Y; Fukui T; Harada Y; Takaha N; Takahara S; Okuyama A
Urology; 2000 Jan; 55(1):151-5. PubMed ID: 10654915
[TBL] [Abstract][Full Text] [Related]
2. Transient rise in serum soluble Fas (APO-1/CD95) in patients undergoing cardiac surgery.
Kawahito K; Misawa Y; Fuse K
Artif Organs; 2000 Aug; 24(8):628-31. PubMed ID: 10971250
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of soluble Fas in the serum of patients with bladder cancer.
Mizutani Y; Yoshida O; Bonavida B
J Urol; 1998 Aug; 160(2):571-6. PubMed ID: 9679930
[TBL] [Abstract][Full Text] [Related]
4. Prolonged intrathecal release of soluble Fas following severe traumatic brain injury in humans.
Lenzlinger PM; Marx A; Trentz O; Kossmann T; Morganti-Kossmann MC
J Neuroimmunol; 2002 Jan; 122(1-2):167-74. PubMed ID: 11777556
[TBL] [Abstract][Full Text] [Related]
5. Increased serum levels of soluble Fas in progressive B-CLL.
Osorio LM; Aguilar-Santelises M; De Santiago A; Hachiya T; Mellstedt H; Jondal M
Eur J Haematol; 2001 May; 66(5):342-6. PubMed ID: 11422415
[TBL] [Abstract][Full Text] [Related]
6. Serum soluble fas level as a prognostic factor in patients with gynecological malignancies.
Konno R; Takano T; Sato S; Yajima A
Clin Cancer Res; 2000 Sep; 6(9):3576-80. PubMed ID: 10999747
[TBL] [Abstract][Full Text] [Related]
7. Serum levels of soluble fas in patients with multinodular goiter.
Andrikoula M; Kolaitis N; Vartholomatos G; Tsatsoulis A
Immunol Invest; 2009; 38(5):398-407. PubMed ID: 19811416
[TBL] [Abstract][Full Text] [Related]
8. Serum sFAS levels are elevated in ANCA-positive vasculitis compared with other autoimmune diseases.
Christensson M; Pettersson E; Eneslätt K; Christensson B; Bratt J; Rantapää-Dahlqvist S; Sundqvist KG
J Clin Immunol; 2002 Jul; 22(4):220-7. PubMed ID: 12148596
[TBL] [Abstract][Full Text] [Related]
9. Elevated serum levels of soluble Fas/APO-1 (CD95) in patients with hepatocellular carcinoma.
Jodo S; Kobayashi S; Nakajima Y; Matsunaga T; Nakayama N; Ogura N; Kayagaki N; Okumura K; Koike T
Clin Exp Immunol; 1998 May; 112(2):166-71. PubMed ID: 9649177
[TBL] [Abstract][Full Text] [Related]
10. Discrepant expression of membrane and soluble isoforms of Fas (CD95/APO-1) in adult T-cell leukaemia: soluble Fas isoform is an independent risk factor for prognosis.
Kamihira S; Yamada Y; Tomonaga M; Sugahara K; Tsuruda K
Br J Haematol; 1999 Dec; 107(4):851-60. PubMed ID: 10606894
[TBL] [Abstract][Full Text] [Related]
11. Soluble and membrane isoforms of Fas/CD95 in fresh adult T-cell leukemia (ATL) cells and ATL-cell lines.
Sugahara K; Yamada Y; Hiragata Y; Matsuo Y; Tsuruda K; Tomonaga M; Maeda T; Atogami S; Tsukasaki K; Kamihira S
Int J Cancer; 1997 Jul; 72(1):128-32. PubMed ID: 9212233
[TBL] [Abstract][Full Text] [Related]
12. Expression of apoptotic regulatory molecules in renal cell carcinoma: elevated expression of Fas ligand.
Olive C; Cheung C; Nicol D; Falk MC
Immunol Cell Biol; 1999 Feb; 77(1):11-8. PubMed ID: 10101681
[TBL] [Abstract][Full Text] [Related]
13. Serum levels of soluble Fas/APO-1 receptor in human retroviral infection and associated diseases.
Kamihira S; Yamada Y; Hiragata Y; Yamaguchi T; Izumikawa K; Matsuo Y; Sugahara K; Tsuruta K; Atogami S; Tsukasaki K; Maeda T; Tomonaga M
Intern Med; 1997 Mar; 36(3):166-70. PubMed ID: 9144006
[TBL] [Abstract][Full Text] [Related]
14. Elevated soluble Fas/APO-1 (CD95) levels in silicosis patients without clinical symptoms of autoimmune diseases or malignant tumours.
Tomokuni A; Aikoh T; Matsuki T; Isozaki Y; Otsuki T; Kita S; Ueki H; Kusaka M; Kishimoto T; Ueki A
Clin Exp Immunol; 1997 Nov; 110(2):303-9. PubMed ID: 9367417
[TBL] [Abstract][Full Text] [Related]
15. An increase of soluble Fas, an inhibitor of apoptosis, associated with progression of COPD.
Yasuda N; Gotoh K; Minatoguchi S; Asano K; Nishigaki K; Nomura M; Ohno A; Watanabe M; Sano H; Kumada H; Sawa T; Fujiwara H
Respir Med; 1998 Aug; 92(8):993-9. PubMed ID: 9893764
[TBL] [Abstract][Full Text] [Related]
16. Serum sFas and tumor tissue FasL negatively correlated with survival in Egyptian patients suffering from breast ductal carcinoma.
El-Sarha AI; Magour GM; Zaki SM; El-Sammak MY
Pathol Oncol Res; 2009 Jun; 15(2):241-50. PubMed ID: 19015953
[TBL] [Abstract][Full Text] [Related]
17. Detection of soluble Fas mRNA using in situ reverse transcription-polymerase chain reaction.
Lee SH; Kim SY; Lee JY; Shin MS; Dong SM; Na EY; Park WS; Kim KM; Kim CS; Kim SH; Yoo NJ
Lab Invest; 1998 Apr; 78(4):453-9. PubMed ID: 9564889
[TBL] [Abstract][Full Text] [Related]
18. Expression of Fas ligand and sFas ligand in human gastric adenocarcinomas.
Lim SC
Oncol Rep; 2002; 9(1):103-7. PubMed ID: 11748465
[TBL] [Abstract][Full Text] [Related]
19. Plasma soluble fas and soluble fas ligand in chronic glomerulonephritis.
Sano H; Asano K; Minatoguchi S; Hiraoka J; Fujisawa K; Nishigaki K; Yasuda N; Kumada H; Takemura M; Ohashi H; Seishima M; Fujiwara T; Fujiwara H
Nephron; 1998 Oct; 80(2):153-61. PubMed ID: 9736812
[TBL] [Abstract][Full Text] [Related]
20. Serum elevations of soluble Fas (CD95/apo-I) concur in deregulating T cell apoptosis during active lupus disease.
Silvestris F; Williams RC; Calvani N; Grinello D; Tucci M; Cafforio P; Dammacco F
Clin Exp Med; 2002 May; 2(1):13-27. PubMed ID: 12049185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
